The U.S. Food and Drug Administration (FDA) has awarded fast track status to investigational therapy CTX001 to treat sickle cell disease. A…
Articles by Patricia Inácio, PhD
The amount of oxygen the blood loses when traveling through the brain could help identify children with sickle cell disease…
Patients with sickle cell disease show the highest rates of readmission and hospitalization within 30 days of being discharged from…
Imara, a pharmaceutical company developing new therapies for sickle cell disease (SCD), has successfully dosed the first patient…
Hypersensitivity to allergens in children with sickle cell anemia may increase the risk of acute chest syndrome, a study suggests. The…
Bluebird bio announced encouraging interim results from the ongoing Phase 1 clinical trial testing its investigational gene therapy LentiGlobin for…
Following a review of studies published in the last decade, experts have updated their recommendations for managing a sickle cell…
Sancilio Pharmaceuticals says its investigational therapy Altemia (SC411) achieved primary and secondary endpoints in a clinical trial with sickle cell…
The new Stanford Center for Definitive and Curative Medicine will foster the development of stem cell and gene therapies for genetic diseases,…
The U.S. Food and Drug Administration (FDA) approved Imbruvica (ibrutinib) for treatment of adult patients with chronic graft-versus-host-disease (cGVHD) who failed…